Literature DB >> 17112427

Treatment of children with osteogenesis imperfecta.

Frank Rauch1, Francis H Glorieux.   

Abstract

Children with moderate to severe forms of osteogenesis imperfecta (OI) require adequate physiotherapy, rehabilitation and orthopedic surgery. Supportive treatment with bisphosphonates can improve the effects of these nonmedicinal treatment modalities. Benefits of bisphosphonate treatment include decreased pain, lower fracture incidence, and better mobility. Among the various bisphosphonates, intravenous pamidronate has been studied in most detail. However, the optimal treatment regimen and the long-term consequences of pamidronate treatment in children are currently unknown. Given these uncertainties, treatment with bisphosphonates during growth should be reserved for patients who have significant clinical problems, such as vertebral compression fractures or long-bone deformities. Medical therapies other than bisphosphonates play a minor role at present. Gene-based therapy currently remains in the realm of preclinical research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112427     DOI: 10.1007/s11914-996-0025-2

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  46 in total

1.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.

Authors:  E M Horwitz; D J Prockop; L A Fitzpatrick; W W Koo; P L Gordon; M Neel; M Sussman; P Orchard; J C Marx; R E Pyeritz; M K Brenner
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

2.  Radiographic features of bisphosphonate therapy in pediatric patients.

Authors:  Leslie E Grissom; H Theodore Harcke
Journal:  Pediatr Radiol       Date:  2003-02-15

3.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

4.  On an attempt to treat primary and secondary osteoporosis with human growth hormone.

Authors:  H P Kruse; F Kuhlencordt
Journal:  Horm Metab Res       Date:  1975-11       Impact factor: 2.936

Review 5.  Modern approach to children with osteogenesis imperfecta.

Authors:  Leonid Zeitlin; François Fassier; Francis H Glorieux
Journal:  J Pediatr Orthop B       Date:  2003-03       Impact factor: 1.041

6.  Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.

Authors:  S A Khan; J A Kanis; S Vasikaran; W F Kline; B K Matuszewski; E V McCloskey; M N Beneton; B J Gertz; D G Sciberras; S D Holland; J Orgee; G M Coombes; S R Rogers; A G Porras
Journal:  J Bone Miner Res       Date:  1997-10       Impact factor: 6.741

7.  Gene targeting in stem cells from individuals with osteogenesis imperfecta.

Authors:  Joel R Chamberlain; Ulrike Schwarze; Pei-Rong Wang; Roli K Hirata; Kurt D Hankenson; James M Pace; Robert A Underwood; Kit M Song; Michael Sussman; Peter H Byers; David W Russell
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

Review 8.  Osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

9.  Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.

Authors:  John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold
Journal:  Toxicol Pathol       Date:  2002 May-Jun       Impact factor: 1.902

10.  Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.

Authors:  L A DiMeglio; L Ford; C McClintock; M Peacock
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

View more
  8 in total

Review 1.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

2.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

Review 3.  Osteoporosis in young adults: pathophysiology, diagnosis, and management.

Authors:  S Ferrari; M L Bianchi; J A Eisman; A J Foldes; S Adami; D A Wahl; J J Stepan; M-C de Vernejoul; J-M Kaufman
Journal:  Osteoporos Int       Date:  2012-06-09       Impact factor: 4.507

Review 4.  Osteogenesis imperfecta:epidemiology and pathophysiology.

Authors:  Elizabeth Martin; Jay R Shapiro
Journal:  Curr Osteoporos Rep       Date:  2007-09       Impact factor: 5.096

5.  [Diagnosis and therapy of osteogenesis imperfecta].

Authors:  A Meurer; T Lewens; D Schmitt; T Vetter; P Drees
Journal:  Orthopade       Date:  2008-01       Impact factor: 1.087

6.  Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: implications for clinical care.

Authors:  Emily L Germain-Lee; Feng-Shu Brennen; Diana Stern; Aditi Kantipuly; Pamela Melvin; Mia S Terkowitz; Jay R Shapiro
Journal:  Pediatr Res       Date:  2015-11-05       Impact factor: 3.756

7.  In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.

Authors:  Cristina Panaroni; Roberta Gioia; Anna Lupi; Roberta Besio; Steven A Goldstein; Jaclynn Kreider; Sergey Leikin; Juan Carlos Vera; Edward L Mertz; Egon Perilli; Fabio Baruffaldi; Isabella Villa; Aurora Farina; Marco Casasco; Giuseppe Cetta; Antonio Rossi; Annalisa Frattini; Joan C Marini; Paolo Vezzoni; Antonella Forlino
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

8.  Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta.

Authors:  Jerry K Y Chan; Cecilia Götherström
Journal:  Front Pharmacol       Date:  2014-10-09       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.